PONS IP, a global consulting firm specialising in intellectual property, attended BIOSPAIN once again this year, the leading international biotechnology event in Spain and one of the most important in Europe, held from 7 to 9 October at Fira de Barcelona.
This year’s edition surpassed the record figures of 2023, bringing together more than 2,000 attendees from over 1,000 companies and entities from 34 countries, consolidating Barcelona as the European epicentre of biotechnology. Under the slogan “Global crossroads, local vibes”, the main challenges and opportunities for the sector in health, investment and sustainability were addressed, with the presence of companies, institutions, regulatory agencies and leading national and international investors.
PONS IP’s attendance at BIOSPAIN 2025 is part of the consulting firm’s long-standing commitment to the sector, as well as to promoting intellectual property culture as a strategic tool for competitiveness in high value-added sectors such as this one. With its own office in Barcelona and a team highly specialised in biotechnology patents, Ana Herrera Arroyo, Director of Patents, Technological Development and Innovation and a European Patent Attorney; Rafael López, Director of Technology Transfer; and Fabián Fernández, Intellectual Property Consultant at the Barcelona office, all attended the event.
“Our presence at BIOSPAIN 2025 reaffirms PONS IP’s commitment to a sector that is at spearheading the best innovation emerging from Spain That is why, now more than ever, protecting intellectual property is key to transforming knowledge into value and that value into investment within a sector in which our country already competes on equal terms in a highly competitive global market,” Ms Herrera stressed.
Biotechnology, Spain’s spearhead in innovation and financing
The data shows the constant vitality existing in the biotechnology sector: according to the European Patent Office (EPO), Spanish applications for European patents reached an all-time high in 2023, with growth of 43% over the last decade. Biotechnology stood out with an increase of 6.1%, ranking among the most active technological areas alongside pharmaceuticals.
In turn, the AseBio 2024 Report confirms that Spanish biotechnology companies brought in €181 million in investment in 2024, through 53 transactions, with 35% coming from international investors. These figures consolidate biotech as one of the most appealing sectors for capital and innovation in Spain.
